Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA.

Ann Surg Oncol. 2014 Oct;21(11):3515-21. doi: 10.1245/s10434-014-3769-4. Epub 2014 May 20.

2.

Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG.

Ann Surg. 2014 Feb;259(2):197-203. doi: 10.1097/SLA.0000000000000348.

3.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.

Arch Surg. 2003 Aug;138(8):859-66.

PMID:
12912744
4.

Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.

Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS.

J Gastrointest Surg. 2015 Jan;19(1):117-23; discussion 123. doi: 10.1007/s11605-014-2615-0. Epub 2014 Aug 26.

PMID:
25155459
5.

Regional Metastatic Behavior of Nonfunctional Pancreatic Neuroendocrine Tumors: Impact of Lymph Node Positivity on Survival.

Jutric Z, Grendar J, Hoen HM, Cho SW, Cassera MA, Newell PH, Hammill CW, Hansen PD, Wolf RF.

Pancreas. 2017 Aug;46(7):898-903. doi: 10.1097/MPA.0000000000000861.

PMID:
28697130
6.

Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors.

Fitzgerald TL, Mosquera C, Vora HS, Vohra NA, Zervos EE.

Am Surg. 2016 Aug;82(8):737-42.

PMID:
27657591
7.

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy.

Fortner JG, Klimstra DS, Senie RT, Maclean BJ.

Ann Surg. 1996 Feb;223(2):147-53.

8.

Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection.

Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N.

J Gastrointest Surg. 2015 Jan;19(1):152-60; discussion 160. doi: 10.1007/s11605-014-2624-z. Epub 2014 Aug 14.

PMID:
25118642
9.

Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?

Sallinen V, Haglund C, Seppänen H.

Surgery. 2015 Dec;158(6):1556-63. doi: 10.1016/j.surg.2015.04.035. Epub 2015 Jun 10.

PMID:
26070847
10.

Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.

Mirkin KA, Hollenbeak CS, Wong J.

J Surg Res. 2017 May 1;211:206-214. doi: 10.1016/j.jss.2016.12.033. Epub 2016 Dec 29.

PMID:
28501118
11.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS.

Surgery. 2013 Oct;154(4):785-91; discussion 791-3. doi: 10.1016/j.surg.2013.07.004.

PMID:
24074416
12.

Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Kazanjian KK, Reber HA, Hines OJ.

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70.

PMID:
16924083
13.

Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF.

Cancer. 2009 Feb 15;115(4):741-51. doi: 10.1002/cncr.24065.

14.

Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.

Birnbaum DJ, Turrini O, Vigano L, Russolillo N, Autret A, Moutardier V, Capussotti L, Le Treut YP, Delpero JR, Hardwigsen J.

Ann Surg Oncol. 2015 Mar;22(3):1000-7. doi: 10.1245/s10434-014-4016-8. Epub 2014 Sep 5.

PMID:
25190116
15.

Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.

Kuo EJ, Salem RR.

Ann Surg Oncol. 2013 Sep;20(9):2815-21. doi: 10.1245/s10434-013-3005-7. Epub 2013 Jun 15.

PMID:
23771245
16.

Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.

Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, Donahue TR.

J Gastrointest Surg. 2013 Dec;17(12):2105-13. doi: 10.1007/s11605-013-2360-9. Epub 2013 Oct 8.

PMID:
24101447
17.
18.

Determinants of surgical resection for pancreatic neuroendocrine tumors.

Doi R.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):610-7. doi: 10.1002/jhbp.224. Epub 2015 Mar 13. Review.

PMID:
25773163
19.

Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.

Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A, Falconi M.

Eur J Cancer. 2012 Jul;48(11):1608-15. doi: 10.1016/j.ejca.2011.10.030. Epub 2011 Nov 28.

PMID:
22129889
20.

Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.

Tsuchikawa T, Hirano S, Tanaka E, Kato K, Matsumoto J, Sichinohe T.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2623-6.

PMID:
22497945

Supplemental Content

Support Center